Alyssa Brown, APRN
Family · Rutland, VTNPI 1225638299
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 156 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by AbbVie at 27.3% of the total. Reporting peaked in 2024 at $1,037 and has fallen 73.8% since, to $272 in 2025. Among family clinicians in VT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 156 payments — averaging $19.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$836
- Novo Nordisk$393
- Boehringer Ingelheim$232
- Lilly USA, LLC$213
- GSK$162
- Pfizer$159
- plus $1K from 18 others
What the payments were for
- Food & beverage$3,059100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 47 | $836 |
| Novo Nordisk | 22 | $393 |
| Boehringer Ingelheim | 11 | $232 |
| Lilly USA, LLC | 11 | $213 |
| GSK | 8 | $162 |
| Pfizer | 9 | $159 |
| Bayer | 4 | $118 |
| Amgen | 6 | $108 |
| AstraZeneca | 4 | $101 |
| Exact Sciences | 4 | $97 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $91 |
| Phathom Pharmaceuticals, Inc. | 4 | $81 |
| Sumitomo Pharma America, Inc. | 3 | $75 |
| E.r. Squibb & Sons, L.L.C. | 3 | $57 |
| Amarin Pharma, Inc. | 3 | $55 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $52 |
| Inspire Medical Systems, Inc. | 1 | $51 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $46 |
| Novartis | 2 | $38 |
| Dexcom, Inc. | 1 | $23 |
| Corcept Therapeutics | 1 | $22 |
| Johnson & Johnson | 1 | $18 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Merck | 1 | $14 |
How this compares
$3,059 in reported general payments places this provider in the 95th percentile of 75 family providers in Vermont.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 79 | $80,549 |
| JardianceEmpagliflozin | 61 | $63,300 |
| FarxigaDapagliflozin Propanediol | 31 | $26,133 |
| JanuviaSitagliptin Phosphate | 25 | $23,679 |
| TrintellixVortioxetine Hydrobromide | 35 | $21,418 |
| Spiriva RespimatTiotropium Bromide | 21 | $11,274 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $8,530 |
| SavellaMilnacipran Hcl | 11 | $6,389 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $5,758 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $5,662 |
| MyrbetriqMirabegron | 13 | $5,268 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 11 | $5,110 |
| Rosuvastatin Calcium | 267 | $2,414 |
| Levothyroxine Sodium | 259 | $1,979 |
| Atorvastatin Calcium | 278 | $1,715 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $393 | $80,54979 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Combivent Respimat | $232 | $80,33294 claims |
| AstraZenecaFarxiga | $101 | $26,13331 claims |
| MerckJanuvia | $14 | $23,67925 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $162 | $19,30136 claims |
| AbbVieSavella | $836 | $6,38911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 75 family providers in Vermont.
Other family in Rutland
- Kristen SheehanRutland$4K
- Linda McMurrayRutland$819
- Kayla CummingsRutland$432
- Kimberly EugairRutland$46
- Rachel GuyVergennes$36K
- Cheryl McNeilSouth Burlington$2K
- Penny BrusoShaftsbury$2K
- Catherine FaldutoBurlington$2K
- Katelyn EmmettBurlington$2K
- Hannah PrevostSt Johnsbury$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.